Bacteria as a double-action sword in cancer
- PMID: 32589907
- DOI: 10.1016/j.bbcan.2020.188388
Bacteria as a double-action sword in cancer
Abstract
Bacteria have long been known as one of the primary causative agents of cancer, however, recent studies suggest that they can be used as a promising agent in cancer therapy. Because of the limitations that conventional treatment faces due to the specific pathophysiology and the tumor environment, there is a great need for the new anticancer therapeutic agents. Bacteriotherapy utilizes live, attenuated strains or toxins, peptides, bacteriocins of the bacteria in the treatment of cancer. Moreover, they are widely used as a vector for delivering genes, peptides, or drugs to the tumor target. Interestingly, it was found that their combination with the conventional therapeutic approaches may enhance the treatment outcome. In the genome editing era, it is feasible to develop a novel generation of therapeutic bacteria with fewer side effects and more efficacy for cancer therapy. Here we review the current knowledge on the dual role of bacteria in the development of cancer as well as cancer therapy.
Keywords: Bacteria; Bacteriotherapy; Cancer; Carcinogen; Treatment.
Copyright © 2020 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Bacteriotherapy in gastrointestinal cancer.Life Sci. 2020 Aug 1;254:117754. doi: 10.1016/j.lfs.2020.117754. Epub 2020 May 7. Life Sci. 2020. PMID: 32389833 Review.
-
Microbes as Medicines: Harnessing the Power of Bacteria in Advancing Cancer Treatment.Int J Mol Sci. 2020 Oct 14;21(20):7575. doi: 10.3390/ijms21207575. Int J Mol Sci. 2020. PMID: 33066447 Free PMC article. Review.
-
Bacteria and cancer: Different sides of the same coin.Life Sci. 2020 Apr 1;246:117398. doi: 10.1016/j.lfs.2020.117398. Epub 2020 Feb 4. Life Sci. 2020. PMID: 32032647 Review.
-
The bacterial instrument as a promising therapy for colon cancer.Int J Colorectal Dis. 2020 Apr;35(4):595-606. doi: 10.1007/s00384-020-03535-9. Epub 2020 Mar 4. Int J Colorectal Dis. 2020. PMID: 32130489 Review.
-
Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities.Cancer Med. 2019 Jun;8(6):3167-3181. doi: 10.1002/cam4.2148. Epub 2019 Apr 5. Cancer Med. 2019. PMID: 30950210 Free PMC article. Review.
Cited by
-
Plantaricin BM-1 decreases viability of SW480 human colorectal cancer cells by inducing caspase-dependent apoptosis.Front Microbiol. 2023 Jan 4;13:1103600. doi: 10.3389/fmicb.2022.1103600. eCollection 2022. Front Microbiol. 2023. PMID: 36687624 Free PMC article.
-
Bacteria and Bacterial Components as Natural Bio-Nanocarriers for Drug and Gene Delivery Systems in Cancer Therapy.Pharmaceutics. 2023 Oct 19;15(10):2490. doi: 10.3390/pharmaceutics15102490. Pharmaceutics. 2023. PMID: 37896250 Free PMC article. Review.
-
Bacterial immunotherapy: is it a weapon in our arsenal in the fight against cancer?Front Immunol. 2023 Nov 27;14:1277677. doi: 10.3389/fimmu.2023.1277677. eCollection 2023. Front Immunol. 2023. PMID: 38090593 Free PMC article. Review.
-
Engineered Endosymbionts that Modulate Primary Macrophage Function and Attenuate Tumor Growth by Shifting the Tumor Microenvironment.ACS Appl Bio Mater. 2025 Jul 21;8(7):5938-5958. doi: 10.1021/acsabm.5c00590. Epub 2025 Jun 24. ACS Appl Bio Mater. 2025. PMID: 40552854 Free PMC article.
-
New Developments and Opportunities of Microbiota in Treating Breast Cancers.Front Microbiol. 2022 May 12;13:818793. doi: 10.3389/fmicb.2022.818793. eCollection 2022. Front Microbiol. 2022. PMID: 35633703 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical